NCT01214616 - BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2010

Primary Completion Date

May 1, 2013

Study Completion Date

May 1, 2013

Conditions

Neoplasms

Interventions

DRUG

afatinib 20mg

patient to receive afatinib low dose po daily in combination with vinorelbine iv

DRUG

afatinib 40mg

patient to receive afatinib high dose po daily in combination with vinorelbine iv

DRUG

vinorelbine IV 25 or 20mg/m2

patient to receive standard dose vinorelbine once a week for four times per cycle

Trial Locations (4)

1200.84.003 Boehringer Ingelheim Investigational Site, Chuo-ku, Osaka, Osaka

1200.84.004 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba

1200.84.001 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1200.84.002 Boehringer Ingelheim Investigational Site, Sakyo-ku, Kyoto, Kyoto